Early Detection Research Network
Team Project

Validation of Molecular Biomarkers for the Early Detection of Lung Cancer in the setting of Indeterminate Pulmonary Nodules (Lung Team Project #2)

LTP2
354
Lenburg, MarcBoston University
Feng, ZidingFred Hutchinson Cancer Research Center
BU: DNA and RNA genomic-wide gene expression profiling. VU: Bronchial proteomic biomarker. Serum based quantitation of CYFRA 21.1, CEA and HE4. Images. UCLA: Circulating exosomal miRNA. Wistar: NanoString. Moffitt: Images. Pittsburgh: CDO1, TAC1, HOXA7, and SOX17.
No design specified.
Proteomics
Lung and Upper Aerodigestive Cancers Research Group
2

To characterize intra or within subject reproducibility and variability To characterize inter or across subject variability by adenoma phenotype (normal vs. adenoma) To evaluate biomarker expression in relation to long term adenoma recurrence

3.1.1   Aim 1 Establish a cohort (n=200) of current and former smokers with indeterminate pulmonary nodules (7mm-25mm) on whom clinical, radiographic and biospecimen repositories are developed and who are followed prospectively until final diagnosis. 3.1.2   Aim 2 Validate the diagnostic accuracy of existing molecular biomarkers in the airway and blood to detect lung cancer in this clinical cohort.
Airway gene-expression biomarker (BU) Airway protein biomarker (VU): LC-MRM-MS analyses Serum glycan biomarker (NYU): Plasma promoter methylation biomarker (JHU): Serum cytokines biomarker (UCLA): Serum/Plasma miRNA biomarker (OSU): Plasma miRNA biomarker (UMD):

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Version 5.0.2